SCHEMBL10153626

SCHEMBL10153626

O=C1NCCNC1c1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.44
TDP1 Q9NUW8 1/20 0.39
PARP10 Q53GL7 1/20 0.39
PARP11 Q9NR21 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GSK3B P49841 2/20 0.38
CYP19A1 P11511 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
KDM4E B2RXH2 1/20 0.38
KDM1A O60341 1/20 0.38
RCOR1 Q9UKL0 1/20 0.38
GFER P55789 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
ALDH1A1 P00352 1/20 0.37
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10506397 0.80 DRD2 (0.45) MAP4K1CYP19A1HTR2AHTR2CHTR2B
SCHEMBL9786155 0.79 TDP1 (0.50) MAP4K1TDP1L3MBTL1GSK3BKDM4E
SCHEMBL380027 0.79 TDP1 (0.50) MAP4K1TDP1L3MBTL1GSK3BKDM4E
SCHEMBL596560 0.78 PRCP (0.44) MAP4K1KDM4EKDM1AGFERALDH1A1
SCHEMBL26986647 0.78 PRCP (0.44) MAP4K1KDM4EKDM1AGFERALDH1A1
SCHEMBL4538638 0.77 PARP10 (0.39) PARP10PARP11HTR2AHTR2CHTR2B
SCHEMBL10508333 0.76 HTR2C (0.51) MAP4K1GSK3BCYP19A1KDM4EKDM1A
SCHEMBL28038489 0.74 HTR2A (0.43) CYP19A1KDM4EKDM1ARCOR1HTR2A
SCHEMBL2486115 0.74 HTR2A (0.41) MAP4K1PARP10GSK3BNISCHHTR2A
SCHEMBL2484568 0.74 HTR2A (0.41) MAP4K1PARP10GSK3BNISCHHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023137634-A1 TRICYCLIC COMPOUND, PREPARATION THEREFOR, PHARMACEUTICAL COMPOSITION AND USE 上海奕拓医药科技有限责任公司 2023-07-27 WO disclosed
US-20140275017-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-09-18 US disclosed
US-20140275017-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-09-18 US disclosed
US-8778957-B2 CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2014-07-15 US disclosed
US-8778957-B2 CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2014-07-15 US disclosed
US-20120010193-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-01-12 US disclosed
US-20120010193-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275017-A1 CGRP RECEPTOR ANTAGONISTS BDKRB1, CALCRL, BDKRB2 MAP4K1 4020/4885TDP1 2690/4885PARP10 2107/4885
US-20120010193-A1 CGRP RECEPTOR ANTAGONISTS BDKRB1, BDKRB2, CALCRL MAP4K1 4079/4885TDP1 2717/4885PARP10 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.